drugset / Trial / NCT02387606

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

NCT02387606

Phase 2 Completed 66 enrolled Janssen Sciences Ireland UC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the antiviral effect of repeated oral dosing of JNJ 53718678 compared to placebo in healthy adult participants infected through inoculation with respiratory syncytial virus (RSV)-A Memphis 37b virus.

Timeline

Start
2015-05-07
Primary completion
2015-09-21
Completion
2015-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilematovir Other / unclassified 75 mg Oral
Subject Rilematovir Other / unclassified 200 mg Oral
Subject Rilematovir Other / unclassified 500 mg Oral